Literature DB >> 6696356

Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia.

S L Gerson, G H Talbot, S Hurwitz, B L Strom, E J Lusk, P A Cassileth.   

Abstract

A case-control study of patients with acute leukemia was done to identify significant risk factors for invasive pulmonary aspergillosis by reviewing the medical histories of 15 cases of pathologically proven invasive pulmonary aspergillosis and 45 controls. A history of lung or sinus disease, smoking, and multiple recurrences of leukemia did not increase the risk of invasive pulmonary aspergillosis. Cases and controls received similar chemotherapeutic regimens, and exposure to aminoglycosides, carbenicillin, trimethoprim-sulfamethoxazole, or corticosteroids was not significantly associated with development of invasive pulmonary aspergillosis. Among the factors tested, only granulocytopenia was associated with development of invasive pulmonary aspergillosis. Early in the course of granulocytopenia, patients developed signs of invasive pulmonary aspergillosis at a rate of approximately 1% per day. As the duration of granulocytopenia increased, the rate increased, approximating 4.3% per day between the 24th and 36th days. Of the 13 patients remaining granulocytopenic at 28 days, 7 had developed signs of invasive pulmonary aspergillosis. For patients with acute leukemia, granulocytopenia persisting longer than three weeks is the major risk factor for developing invasive pulmonary aspergillosis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6696356     DOI: 10.7326/0003-4819-100-3-345

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  126 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  In vitro models for studying toxicity of antifungal agents.

Authors:  V Joly; J Bolard; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

3.  Invasive aspergillosis in immunosuppressed patients: potential hazard of hospital building work.

Authors:  A G Dewhurst; M J Cooper; S M Khan; A P Pallett; J R Dathan
Journal:  BMJ       Date:  1990-10-06

4.  Invasive pulmonary aspergillosis in non-immunocompromised patients.

Authors:  J L Hovenden; F Nicklason; R A Barnes
Journal:  BMJ       Date:  1991-03-09

5.  Influenza Suppresses Neutrophil Recruitment to the Lung and Exacerbates Secondary Invasive Pulmonary Aspergillosis.

Authors:  Joshua M Tobin; Kara L Nickolich; Krishnaveni Ramanan; Matthew J Pilewski; Kristina D Lamens; John F Alcorn; Keven M Robinson
Journal:  J Immunol       Date:  2020-06-10       Impact factor: 5.422

6.  Specific binding of human fibrinogen fragment D to Aspergillus fumigatus conidia.

Authors:  V Annaix; J P Bouchara; G Larcher; D Chabasse; G Tronchin
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

7.  Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis.

Authors:  Viviane Balloy; Michel Huerre; Jean-Paul Latgé; Michel Chignard
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

8.  The radiological spectrum of invasive aspergillosis in children: a 10-year review.

Authors:  Karen E Thomas; Catherine M Owens; Paul A Veys; Vas Novelli; Vera Costoli
Journal:  Pediatr Radiol       Date:  2003-05-09

9.  Immunomodulation Therapy for Invasive Aspergillosis: Discussion on Myeloid Growth Factors, Recombinant Cytokines, and Antifungal Drug Immune Modulation.

Authors:  Amar Safdar
Journal:  Curr Fungal Infect Rep       Date:  2010-03

10.  The developmentally regulated alb1 gene of Aspergillus fumigatus: its role in modulation of conidial morphology and virulence.

Authors:  H F Tsai; Y C Chang; R G Washburn; M H Wheeler; K J Kwon-Chung
Journal:  J Bacteriol       Date:  1998-06       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.